The majority of human anogenital carcinomas show evidence of papillomavirus infection. To facilitate viral replication, viruses disable key cellular responses which would otherwise precipitate cell suicide. An obligate factor in one such response is the p53 tumour suppressor protein. p53 gene mutation is an infrequent event in anogenital cancer, apparently due to the action of HPV E6 protein, which inhibits wild-type p53 function by stimulating the degradation of p53 protein. p53 is required for the apoptotic response that is triggered in untransformed cells following inappropriate cell-cycling. E6 directed inhibition of p53 function thus facilitates the survival of transformed cells. We have developed a genetically tractable model that reports E6 proteinmediated human p53 inactivation in the ®ssion yeast Schizosaccharomyces pombe. Functional dissection of the requirements for E6 directed inhibition in this system reveal an absolute requirement for the presence of both E6 protein and the human E3 ubiquitin ligase, E6-AP. Using a de®ned set of E6 mutants we show that degradation of p53 protein rather than E6/p53 association is likely required for E6-mediated inhibition. This S. pombe based system represents a candidate screen for novel antiviral agents that act by disrupting the E6/E6-AP/p53 interaction.
Introduction
Inactivation of the p53 transcription factor is a frequent event in human cancer with around 40% of all human tumours possessing a mutated p53 gene (Harris, 1996) . However, it is evident that the involvement of p53 inactivation in tumourigenesis is even more common than the mutation statistics reveal. Genetic changes resulting in overproduction of the p53 inactivating factor(s) MDM2 can by-pass the apparent requirement for p53 mutation in the development of malignancy (Oliner et al., 1992; Reifenberger et al., 1993; Landers et al., 1994; Berberich and Cole, 1994) . Furthermore, several tumour associated viruses encode p53 interacting proteins (Lane and Crawford, 1979; Linzer and Levine, 1979; Sarnow et al., 1982; Werness et al., 1990; Wang et al., 1994; Truant et al., 1995) whose presence appears to alleviate the requirement for p53 gene mutation in the initiation of viral associated malignancy. Many of these have been reported to inhibit p53 transcriptional transactivation activity (Mietz et al., 1992; Yew and Berk, 1992; Wang et al., 1994; Truant et al., 1995) , an activity that appears to be critical for transformation suppressor function. The most extensively studied of these viruses are the human papilloma viruses (HPV).
Some 90% of human anogenital tumours lack detectable p53 mutations, whereas the frequency of HPV infection is high (Crook et al., 1991a,b; 1992; Schener et al., 1991; Wrede et al., 1991) . It appears that p53 mutations are not selected during the genesis of these malignancies, at least until the late metastatic stage , and evidence suggests that p53 protein is inactivated instead by an intrinsic activity of the viral antigen E6. Papilloma virus infected cells contain low to undetectable p53 protein levels despite retention of wild-type p53 mRNA levels (Matlashewski et al., 1986) . Expression in mammalian cells of E6 proteins from the high-risk HPV subtypes is sucient to de-stabilise p53 (Mietz et al., 1992) , and co-translation of p53 and HPV16 or 18 E6 in rabbit reticulocyte lysate leads to ubiquitination and proteolytic degradation of p53 (Schener et al., 1990) . These data suggest that degradation is responsible for the low levels of p53 protein in HPV infected cells and consequent loss of p53 function. E6-AP (E6 associated protein) is a 100 kD cellular protein that mediates the association between E6 and p53 (Huibregtse et al., 1991 . E6-AP encodes an E3 ubiquitin ligase activity . Ubiquitination of a peptide destined for degradation often occurs via the sequential transfer of a ubiquitin thioester from E1 ubiquitin activating enzyme to E2 ubiquitin conjugating enzyme to E3 ubiquitin protein ligase and subsequent ligation of ubiquitin to the targeted protein by the E3 (Hershko and Ciechanover, 1992; Varshavsky, 1992) . E6-AP is an active component of this cascade, accepting the ubiquitin moiety and transfering it directly to p53 . Whether E6-AP is involved in the degradation of p53 in the absence of E6 is unknown. Although there is little detectable E6-AP/p53 association in the absence of E6 (Huibregtse et al., 1991 , it is possible that a cellular E6-like factor is required to mediate the interaction. E6-AP has ubiquitin protein ligase activity in the absence of E6 and is able to label a number of unidenti®ed cellular proteins in vitro .
Here, we describe the development of a genetic system, based in Schizosaccharomyces pombe, that reports the inactivation of human p53 by high-risk papilloma virus E6 proteins. We demonstrate an absolute dual requirement for both exogenous E6 and human E6-AP in this assay system. Using a prede®ned group of E6 mutants (Crook et al., 1991c; Pim et al., 1994) we show that retention of ubiquitin-dependent p53 degradation in vitro correlates with inhibitory activity in vivo. E6 variants reported elsewhere to be defective in degradation assays in vitro, but retaining inhibition of p53 transactivator activity in transient transfection assays, are inactive in this system, raising the possibility of additional cellular E6-associated factors that cooperate in parallel to the degradation pathway and which lack functional homologues in ®ssion yeast. The system has potential for the genetic and functional dissection of the p53/E6/E6-AP interaction, and could be exploited in the search for novel papillomavirus-speci®c viricides.
Results

The model system
The experimental system is shown schematically in Figure 1 . Human p53 can direct sequence-speci®c gene expression in S. pombe and the growth status of strain 53/4Z is conditional on the transcription transactivation activity of the expressed human p53 protein. This strain contains a human p53 cDNA, under control of the constitutive adh1+ promoter, integrated at the leu1+ locus and single copies of both the S. pombe ura4+ gene and the lacZ gene integrated at the ade6 and arg3 loci respectively. Both ura4+ and lacZ expression are controlled by p53-responsive promoters. Expression of the ura4+ gene, which encodes orotidine 5' phosphate decarboxylase (OMPdecase), confers uracil prototrophy but is lethal in the presence of 5-Fluoroorotic acid (5-FOA). Conversely, cells in which ura4+ expression is suppressed are uracil auxotrophic but exhibit 5-FOA resistance. Inhibitors of p53 transactivator activity revert the strain to 5-FOA resistance. The integrated p53-responsive lacZ gene serves as a secondary reporter.
Testing E6 proteins for activity in the`no-hybrids' system.
In earlier work, we showed that expression of the simian virus 40 large T antigen protein (SV40 Tag), human mdm2 protein, or a panel of human tumour derived mutant p53 proteins in 53/4Z, resulted in profound inhibition of p53 transcription transactivation activity and conversion of the strain to uracil auxotrophy and 5-FOA resistance (Waddell and Jenkins, manuscript in preparation) . We wished to model the interaction between the high risk papillomaviruses and human p53 in this system and so tested a set of HPV E6 proteins for their ability to inactivate p53. E6 expressing vectors (pREP1/pREP9E10), together with a Tag expression vector (pREP1-SV40T) as positive control, were transformed into 53/ 4Z and transformants were selected the presence of the viral antigen episome. Transformant colonies were radially streaked onto selective media containing 5-FOA to select for inhibition of p53 activity. Whereas the control large T antigen conferred resistance to 5-FOA, strains expressing either HPV type HPV type 6E6, 16 E6 or 18E6 remained 5-FOA sensitive ( Figure  2 ). Identical results were obtained with both 9E10 tagged and non-tagged constructs. Although only T ag showed p53 inhibitory activity in Figure 2 , T ag is the only protein that has been conclusively shown to exert its eect directly, being able to inhibit p53 transactivation in a reconstituted transcription system in vitro (Farmer et al., 1992) . For this reason it was concluded that perhaps inhibition by E6 proteins involved an additional cellular factor that lacked a functional homologue in ®ssion yeast.
E6-AP permits p53 inactivation by E6 in ®ssion yeast
Knowing that E6-AP might be crucial for HPV E6-mediated inhibition of p53 and that it is at least a b Figure 1 Schematic representation of the`no-hybrids' experimental system. (a) Strain 534Z exogenous human p53 provided by an integrated expression cassette confers uracil prototrophy and therefore sensitivity to 5-FOA via activation of a p53-responsive ura4+ gene. The strain also harbours an integrated p53 responsive lacZ gene as a secondary reporter gene. (b) Transformation of the 534Z strain with a vector encoding a p53 inhibitory molecule converts the strain to 5-FOA resistance Figure 2 Testing E6 proteins for inhibitory activity. Transformants of the 534Z strain with pREP1 SV40T, pREP1 6E6, pREP1 16E6 and pREP1 18E6 were streaked onto a leucine de®cient EMM plate containing 1 mg/ml 5-FOA prepared as described in the Materials and methods. Streaks were left to grow at 308C for 4 days essential for accelerated degradation by the ubiquitin pathway we reasoned that exogenous E6-AP might also be required for p53 inactivation in yeast. E6-AP activity, de®ned as the ability of a fraction to support the in vitro degradation of human p53 and to be able to bind to E6 (Huibregtse et al., 1991 , has been found in extracts of all mammalian cells tested but is absent in Spodoptera (Martin Schener, personal communication) and wheat germ lysate . A cDNA encoding E6-AP was placed under control of the reduced activity nmt41 promoter (Basi et al., 1993) in the arg3+ selectable expression vector paR341CD (Waddell and Jenkins, manuscript in preparation) . By expressing E6-AP from a reduced output promoter we hoped to reduce the possibility that high levels of E6-AP would result in inhibition of p53 via an overexpression-driven association, rather than degradation. We anticipated that lower level expression of E6-AP would be sucient to inactivate p53 in the presence of E6 since the ubiquitination mechanism, assumed to be necessary for inhibitory activity, is enzymatic.
Strain 53/4Z was co-transformed with vectors expressing either E6-AP or 18E6 alone or with both E6-AP and 18E6 together (paR341.E6-AP with empty pREP9E10 or pREP9E10.18E6 and pREP9E10.18E6 with paR341.E6-AP). Transformants prototrophic for leucine and arginine were re-streaked on selective plates containing 5-FOA. The results are displayed in Figure  3 . The dual presence of 18E6 and E6-AP is sucient to abrogate p53 activity and revert 53/4Z to a 5-FOA resistant phenotype. In each case however, neither E6 nor E6-AP alone had detectable eect. These results indicate that, at least in ®ssion yeast and at these relative expression levels, E6 is unable to inhibit p53 in the absence of cooperation by E6-AP.
Inhibition versus degradation
To ask whether p53 degradation was necessary for inhibition, a set of site directed HPV type 16 and type 18 E6 mutants (Crook et al., 1991c; Pim et al., 1994) were assayed for p53 inactivation activity. The 16 E6 mutants, YYH (a triple amino acid replacement at codons 45, 47 and 49) and D9 ± 13 (a 5 amino acid intragenic deletion from codons 9 ± 13), are unable to stimulate in vitro degradation but can still bind to p53. The other 16 E6 mutant, D106 ± 110 (a 5 amino acid deletion from 106 ± 110) cannot bind or degrade p53 in vitro and so can be considered totally inactive. The 18 E6 mutant DA is reported to inhibit p53 transactivation whilst having lost the ability to stimulate ubiquitin dependent degradation in vitro. DF has retained degradation activity but paradoxically was reported not to inhibit p53 transactivation whilst M2 can neither inhibit nor degrade p53 and so can be considered a dead version of 18 E6.
These E6 mutants together with PAb9E10 epitope (Evan et al., 1985) aminoterminal tagged variants were inserted under the control of the nmt1+ promoter in the vector pREP1 (Maundrell 1993 ) and cotransformed into strain 53/4Z with either control vector paR341 or paR341/E6-AP. As a negative control of vector expressing the E6 protein of HPV type 6, a low-risk non-cancer associated papilloma virus, was included. As expected, all E6 transformants were sensitive to 5-FOA in the absence of E6-AP (data not shown). Restreaks of the 16E6/E6-AP co-transformants on 5-FOA selective medium are shown in Figure 4a and those of 18E6/E6-AP in Figure 5a . Strikingly, the only E6 constructs capable of supporting p53 inactivation are the wild-type 16 E6, 18 E6 and the DF mutant that retained the ability to degrade p53 in vitro. All the other 16 and 18 E6 mutants reported elsewhere to be defective in stimulating in vitro p53 degradation fail to convert the strain to 5-FOA resistance, demonstrating a perfect correlation between degradation competence in vitro and inhibition of p53 activity in this model system. Identical results were obtained using the epitope tagged and untagged E6 variants.
Relative expression of the E6 proteins.
Expression patterns of wild-type and mutant E6 proteins were analysed by western blotting. Figure 4b demonstrates that the 16E6 constructs are similarly expressed with the exception of the dead mutant, D106 ± 110, which is present at signi®cantly lower levels. The degradation defective mutants D9 ± 13 and YYH are expressed at similar or higher levels to wildtype 16E6 and therefore inactivity is unlikely to be due to insucient protein levels. Figure 5b shows that the 18E6 constructs are similarly expressed. The least abundant 18E6 variant is DF which retains inhibitory activity suggesting that the lack of inhibitory activity exhibited by mutant DA is unlikely to be a result of low protein levels. As a loading control, the same ®lters were stripped and reprobed with anti-a-tubulin antibody (upper panels of Figures 4b and 5b ).
Conclusions
Here we describe a genetic system, based in ®ssion yeast, which reports high-risk papilloma virus E6 protein-mediated inactivation of human p53. The system has signi®cant potential for the genetic Figure 3 E6-AP is required for p53 inactivation by E6. The 534Z strain was transformed with pREP9E10.18E6 and paR341X, pREP9E10 and paR341X.E6-AP or pREP9E10.18E6 and paR341X.E6-AP Leucine and arginine double prototrophs were streaked onto 5-FOA selective media and incubated at 308C for 4 days Modelling HPV E6 proteins in fission yeast S Waddell and JR Jenkins dissection of the E6/E6-AP/p53 interaction, and possibly more general aspects of ubiquitination mediated degradation processes.
Given the known requirement for the presence of E6-AP protein in E6 mediated p53 degradation in vitro, the failure of HPV16 or 18 E6 proteins alone to inhibit p53 function (Figure 2 ) indicated the possible absence of a compatible E6-AP homologue in ®ssion yeast. Accordingly, transformations were performed directing coexpression of E6 and E6-AP proteins in the reporter strain 534Z. The results (Figure 3) showed unequivocally that although neither human E6-AP protein nor E6 proteins alone had detectable eect, the combination of E6 together with E6-AP resulted in inhibition of p53 transactivator activity.
Assays using a set of prede®ned E6 mutant proteins (Crook et al., 1991c; Pim et al., 1994) , of which three bind p53 without subsequent degradation, revealed that degradation appears to segregate with inhibitory activity. Given that the 16 E6 mutants YYH and D9 ± 13 E6 and the 18 E6 mutant DA bind p53 (Crook et al., 1991c; Pim et al., 1994) , the data support the notion that degradation by the ubiquitin pathway is essential for E6-mediated inhibition of p53 activity in 16E6 stimulated p53 degradation is required for inhibitory activity. (a). The 534Z strain was co-transformed with empty pREP9E10 or pREP9E10 encoding 6E6, 16E6, or the in vitro degradation de®cient E6 mutants D9 ± 13, D106 ± 110 and YYH with paR341X.E6-AP. Leucine and arginine double prototrophs were radially streaked to selective media containing 5-FOA. (b). Native protein extracts were prepared from 50 ml mid-logarithmic liquid cultures grown at 308C. Protein concentration was determined by the method of Bradford (1976) using the BioRad protein assay kit. 50 mg of total protein was loaded per lane. Extracts were subjected to 15% SDS ± PAGE and transferred to a nitrocellulose ®lter. The ®lter was ®rst immunoblotted with PAb9E10 (bottom panel). As a loading control, the ®lter was stripped and reprobed with anti-a-tubulin antibody (top panel). PAb9E10 and anti-a-tubulin antibodies were used at 1:1000 dilution. Hybridised primary antibody was visualised by HRP-coupled secondary sheep anti-mouse Ig antibody (1:5000) followed by ECL
Figure 5 18E6 stimulated p53 degradation is required for inhibitory activity. (a) The 534Z strain was co-transformed with empty pREP9E10 or pREP9E10 encoding 18E6 or the in vitro degradation de®cient E6 mutants DA, DF and M2 with paR341X.E6-AP. Leucine and arginine double prototrophs were radially streaked to selective media containing 5-FOA. (b) Native protein extracts were prepared from 50 ml mid-logarithmic liquid cultures grown at 308C. Protein concentration was determined by the method of Bradford (1976) using the BioRad protein assay kit. 50 mg of total protein was loaded per lane. Extracts were subjected to 15% SDS ± PAGE and transferred to a nitrocellulose ®lter. The ®lter was ®rst immunoblotted with PAb9E10 (bottom panel). As a loading control, the ®lter was stripped and reprobed with anti-a-tubulin antibody (top panel). PAb9E10 and anti-atubulin antibodies were used at 1:1000 dilution. Hybridised primary antibody was visualised by HRP-coupled secondary sheep anti-mouse Ig antibody (1:5000) followed by ECL this system. Strikingly, the only mutant reported to have retained the ability to stimulate p53 degradation in vitro, DA (Pim et al., 1994) , is the only mutant of this set to display inhibitory activity in S. pombe. Other reports have concluded that p53-binding by E6 alone can be sucient to inhibit p53 activity (Crook et al., 1991c; Pim et al., 1994) . Interestingly, the mutants D9 ± 13, YYH and DA, reported to be degradation de®cient but inhibition pro®cient, lack any activity in our system. E6 appears to associate with at least ®ve other cellular proteins in addition to p53 and E6-AP (Keen et al., 1994) and it may be that the degradationindependent inhibitory activity observed in these previous studies is dependent on an additional E6-associated cellular protein which lacks a functional homologue in ®ssion yeast. Alternatively, D9 ± 13 and YYH, and the 18E6 mutant DA are still capable of binding p53, but have lost E6-AP binding and so as well as having lost the ability to trigger degradation they fail to nucleate E6/E6-AP/p53 complexes which is necessary for inhibitory activity in yeast. Measurement of p53 breakdown kinetics in cells expressing E6-AP alone and E6-AP with E6 will determine whether degradation is accelerated, confirming whether E6-AP is working enzymatically. Nevertheless, our studies with the E6 mutant variants suggests that degradation is necessary for detectable inhibitory activity in this assay system. Despite the apparent lack of a yeast E6-AP homologue, our results indicate a degree of evolutionary conservation between the cellular ubiquitination pathways of ®ssion yeast and human cells. The cellular attachment of ubiquitin to a peptide destined for degradation occurs by sequential transfer of a ubiquitin thioester from E1 ubiquitin activating enzyme to E2 ubiquitin conjugating enzyme to E3 ubiquitin protein ligases with subsequent ligation of ubiquitin to the targeted protein by E3 (Varshavsky, 1992; Hershko and Ciechanover, 1992 ). It appears that there are many dierent E2 (Matuschewski et al., 1996; Nuber et al., 1996) and E3 proteins in the cell and this variety is expected to be essential for the speci®city of ubiquitin transfer to the relevant proteins. The E2 ubiquitin conjugating enzymes present in ®ssion yeast are likely capable of transferring a ubiquitin moiety to the mammalian E6-AP ubiquitin ligase (an E3) providing evidence of functional conservation (so much so that they can interact cross species from yeast to human) but also indicating that E6-AP and E6 are probably sucient for providing ubiquitin transfer speci®city. Additionally, since E6/E6-AP is exogenous to yeast there is presumably considerable promiscuity in the association between E3 and E2 proteins.
It is not known whether E6-AP is involved in the regulation of p53 activity in normal cells. However, although antisense blockade of E6-AP protein expression in HPV 18 infected cells results in upregulation of endogenous p53 protein levels, equivalent blockade of normal cells has no eect on p53 expression (BeerRomero et al., 1997) , suggesting that cellular regulation of p53 levels may occur via another pathway. Alternatively, in the uninfected cell, a cellular E6-like protein may regulate E6-AP/p53 interaction, but that in this instance, E6-AP protein levels are not directly rate-limiting. Puri®ed E6-AP exhibits ubiquitin ligase activity in vitro in the absence of E6, and can ubiquitinate a number of unidenti®ed cellular proteins, presumably in the absence of any accessory factor .
Here we show that in a ®ssion yeast system E6-AP expression alone cannot inhibit p53 activity. Since yeast cell growth is conditional on functional E6 protein complementation of E6-AP directed p53 inactivation, this system represents a credible vehicle for the isolation of cellular E6-like factors.
The system is also suitable for dissection of the precise requirements for E6/E6-AP/p53 complex formation and forms the basis of a potential drug screen for novel antiviral and anticancer agents. In mammalian cells, inactivation of p53 by E6 is required to block apoptosis induced by HPV E7 proteinmediated uncoupling of cellular E2F-1 family transcription factors from the pocket proteins. Two independent but similar reports of transgenic expression of E7 and/or E6 in the developing mouse eye have shown that E7 expression induces apoptosis in cells which would be undergoing terminal dierentiation. However, co-ordinate expression of E7 with E6 induces tumours (Pan and Griep, 1994; Howes et al., 1994) . We predict that pharmacological inhibition of the E6/E6-AP/p53 interaction would restore the apoptotic response of cells expressing E6 proteins and trigger the systemic ablation of both infected and neoplastic cells via the intrinsic p53-dependent apoptotic pathway.
Materials and methods
Strains
The Schizosaccharomyces pombe strain used in this study will be described elsewhere (Waddell and Jenkins, manuscript in preparation) . It harbours an integrated human p53 cDNA (leu1+ locus) driven by the constitutive adh1+ promoter and two p53 responsive reporter genes, ura4 and lacZ. Both of these reporters are also integrated in the ade6+ and arg3+ locus respectively. The p53 responsive promoter region employed contains the consensus DNA binding motif of Funk et al. (1992) and is described in Tarunina and Jenkins (1993) . All progenitor strains were obtained from the National Collection of Yeast Cultures, Norwich, UK.
Media and culture conditions S. pombe media was as previously described (Moreno et al., 1991) . Where required, L-arginine was added to a ®nal concentration of 1 mg/ml (Van Huel et al., 1992) . The 5-Fluoroorotic acid (5-FOA): uracil ratio in the media was 1 mg/ml : 0.05 mg/ml, in accord with Grimm et al. (1988) . A constituent of the 5-FOA medium described by Grimm et al. (1988) is yeast nitrogen base which contains thiamine. The relative concentration in this 5-FOA media is 0.2 mM and so nmt1+ promoter driven expression would be predicted to be minimal. In this study, 5-FOA was added to EMM plates to exclude thiamine.
Transformants were radially streaked onto selective EMM 5-FOA plates after suspension in 10 ml of sterile water. All liquid cultures and plates were incubated at 308C.
Yeast transformation
S. pombe were transformed with the Lithium acetate method as previously described (Moreno et al., 1991) .
Plasmids
A modi®ed pREP1 (Maundrell, 1993) containing an amino terminal anti-c-myc PAb9E10 epitope (Evan et al., 1985) tag, in single letter amino acid notation MEQKLISEEDL, was constructed by insertion of a double stranded oligonucleotide and was used for expression of all HPV E6 clones. All E6 variants were fused in frame to the epitope tag following 10 cycle PCR with Pfu polymerase. Initiating methionine codons were removed to increase expression of the tagged variant. Constructs were veri®ed by sequencing and experiments were repeated with nontagged, non-PCR ampli®ed, E6 expression constructs. A human E6-AP clone encoding the 95 kDa form was cloned under the control of the crippled nmt1+ promoter from pREP41 (Basi et al., 1993) in a paR3 (Waddell and Jenkins, 1995) expression vector variant. Untagged E6 variants were made by direct excision from mammalian cell expression vectors and ligation into the pREP1 polylinker. A pREP1 vector expressing Simian virus 40 large T antigen was employed where indicated.
Protein extraction
Native cell lysates were prepared by glass bead-bashing as described (Moreno et al., 1991) . Protein extract concentration was measured by the Bradford method (BioRad) and extracts were stored at 7708C.
Immunoblotting 50 mg of total protein extracts was analysed by SDS ± PAGE (15% acrylamide) and transferred to nitrocellulose membrane (BA85, Schleicher and Schuell) using a BioRad Trans-blot cell. After blocking the ®lter with 10% skimmed milk and 0.1% Tween-20, ®lters were probed with PAb9E10 (Evan et al., 1985) and hybridised primary antibody was visualised via HRP-coupled secondary antibody using the chemiluminescence procedure, ECL, as described by the manufacturer (Amersham). For the loading control, ®lters were stripped by 508C incubation in stripping buer (100 mM 2-mercaptoethanol, 2% SDS, 62.5 mM Tris-HCl pH 6.7), washed extensively with PBS/0.1% Tween-20 and reblocked with 10% skimmed milk and 0.1% Tween-20. Filters were then probed with anti-tubulin antibody (Sigma T-5168) and visualised by ECL.
